How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

887 results for

Rivastigmine

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. How to minimise the risks of medication errors with rivastigmine patches

How to minimise the risks of medication errors with rivastigmine patches How to minimise the risks of medication errors with rivastigmine patches – SPS - Specialist Pharmacy Service – The first stop for professional medicines advice Menu · · 29th March 2019 This updated Q&A aims to raise awareness on the types of medication errors reported with rivastigmine patches, as well as highlighting strategies to improve medication safety on the prescribing and administration of these patches

2019 Specialist Pharmacy Services

2. Rivastigmine for the treatment of dementia associated with Alzheimer's disease or Parkinson's disease

Rivastigmine for the treatment of dementia associated with Alzheimer's disease or Parkinson's disease ACE Technology Guidances Rivastigmine patch formulation (4.6mg/24h and 9.5mg/24h) for the treatment of moderately severe dementia, and behavioural symptoms of dementia, associated with Parkinson's disease.Rivastigmine patch formulation (4.6mg/24h, 9.5mg/24h and 13.3mg/24h) for the treatment of moderately severe dementia, and behavioural symptoms of dementia, associated with Alzheimer's disease (...) . Conditions should be confirmed by a specialist physician (geriatrician, neurologist or psychiatrist) with experience in the treatment of dementia. Treatment should be continued only when it is considered to be having a worthwhile effect on cognitive, global, functional or behavioural symptoms. Subsidy statusRivastigmine patch formulation (4.6mg/24h, 9.5mg/24h and 13.3mg/24h) is recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indications. Rivastigmine should

2018 ACE Technology Guidance (Singapore)

3. How to minimise the risks of medication errors with rivastigmine patches

How to minimise the risks of medication errors with rivastigmine patches application/msword

2017 Specialist Pharmacy Services

4. Risk of rhabdomyolysis with donepezil compared with rivastigmine or galantamine: a population-based cohort study Full Text available with Trip Pro

Risk of rhabdomyolysis with donepezil compared with rivastigmine or galantamine: a population-based cohort study Donepezil, rivastigmine and galantamine are popular cholinesterase inhibitors used to manage the symptoms of Alzheimer disease and other dementias; regulatory agencies in several countries warn about a possible risk of rhabdomyolysis with donepezil, based on information from case reports. Our goal was to investigate the 30-day risk of admission to hospital with rhabdomyolysis (...) associated with initiating donepezil versus other cholinesterase inhibitors.We conducted a retrospective cohort study in Ontario, Canada, from 2002 to 2017. Participants were adults aged 66 years or older with a newly dispensed prescription for donepezil compared with rivastigmine or galantamine. The primary outcome was hospital admission with rhabdomyolysis (assessed using hospital diagnostic codes) within 30 days of a new prescription of a cholinesterase inhibitor. Odds ratios were estimated using

2019 EvidenceUpdates

5. Rivastigmine for Alzheimer's disease. Full Text available with Trip Pro

Rivastigmine for Alzheimer's disease. Alzheimer's disease is the commonest cause of dementia affecting older people. One of the therapeutic strategies aimed at ameliorating the clinical manifestations of Alzheimer's disease is to enhance cholinergic neurotransmission in the brain by the use of cholinesterase inhibitors to delay the breakdown of acetylcholine released into synaptic clefts. Tacrine, the first of the cholinesterase inhibitors to undergo extensive trials for this purpose (...) , was associated with significant adverse effects including hepatotoxicity. Other cholinesterase inhibitors, including rivastigmine, with superior properties in terms of specificity of action and lower risk of adverse effects have since been introduced. Rivastigmine has received approval for use in 60 countries including all member states of the European Union and the USA.To determine the clinical efficacy and safety of rivastigmine for patients with dementia of Alzheimer's type.We searched ALOIS, the Cochrane

2015 Cochrane

6. Rivastigmine in Parkinson's Disease Dementia with Orthostatic Hypotension. Full Text available with Trip Pro

Rivastigmine in Parkinson's Disease Dementia with Orthostatic Hypotension. To evaluate if the cognitive benefit of rivastigmine is affected by the presence of orthostatic hypotension (OH) in patients with Parkinson's disease dementia (PDD).We conducted a post-hoc analysis on 1,047 PDD patients from two randomized controlled trials comparing rivastigmine vs. placebo at week 24 (n = 501) and rivastigmine patch vs. capsule at week 76 (n = 546). A drop ≥20 mm Hg in systolic or ≥ 10 in diastolic (...) %) in the OH+ placebo arm. The placebo-adjusted effect of rivastigmine on ADAS-Cog at week 24 was 5.6 ± 1.2 for OH+ and 1.9 ± 0.9 in OH- (p = 0.0165). Among OH+ subjects, the MDRS change from baseline at week 76 was higher for rivastigmine capsules vs. patch (10.6 ± 2.9 vs. -1.5 ± 3.0) (p = 0.031). The overall prevalence of OH+ was lower for rivastigmine than placebo at week 24 (28.3% vs 44.6%) (p = 0.0476).The cognitive benefit from rivastigmine is larger in PDD patients with OH, possibly mediated

2020 Annals of Neurology

7. Rivastigmine 3M Health Care Ltd

Rivastigmine 3M Health Care Ltd EMA/58565/2014 EMEA/H/C/003824 EPAR summary for the public Rivastigmine 3M Health Care Ltd rivastigmine This is a summary of the European public assessment report (EPAR) for Rivastigmine 3M Health Care Ltd. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Rivastigmine 3M Health Care Ltd. For practical information about using (...) Rivastigmine 3M Health Care Ltd, patients should read the package leaflet or contact their doctor or pharmacist. What is Rivastigmine 3M Health Care Ltd and what is it used for? Rivastigmine 3M Health Care Ltd is a medicine that contains the active substance rivastigmine. Rivastigmine 3M Health Care Ltd is used to treat patients with mild to moderately severe Alzheimer’s dementia, a progressive brain disorder that gradually affects memory, intellectual ability and behaviour. Rivastigmine 3M Health Care Ltd

2014 European Medicines Agency - EPARs

8. Rivastigmine does not alter cocaine-induced subjective effects or self-administration. (Abstract)

Rivastigmine does not alter cocaine-induced subjective effects or self-administration. Acetylcholinergic (ACh) neurons interface with the mesolimbic dopamine pathway implicated in addiction, and acetylcholinesterase inhibitors (AChEis) have been shown to reduce the immediate effects of cocaine and amount used. Our study is the first to examine if the safe and low-interaction AChEi rivastigmine (riv) alters the subjective effects produced by cocaine administration.Cocaine-dependent subjects were (...) subjects were randomized to placebo (n = 16), riv 3 mg (n = 13), or riv 6 mg (n = 12). All subjects completed the study and there were no demographic differences between treatment groups. Pre- and post- treatment, there were no significant pharmacokinetic differences (blood levels of cocaine, BE, EME) following cocaine administration. In a two-way ANOVA, IV cocaine significantly increased positive VAS category ratings compared to placebo, but rivastigmine treatment at either dose had no significant

2019 Pharmacology, biochemistry, and behavior Controlled trial quality: uncertain

9. Effect of Rivastigmine (Acetyl Cholinesterase Inhibitor) versus Placebo on Manic Episodes in Patients with Bipolar Disorders: Results from a Double Blind, Randomized, Placebo-Controlled Clinical Trial. (Abstract)

Effect of Rivastigmine (Acetyl Cholinesterase Inhibitor) versus Placebo on Manic Episodes in Patients with Bipolar Disorders: Results from a Double Blind, Randomized, Placebo-Controlled Clinical Trial. To treat patients with bipolar disorders (BPD) during the acute phase, the standard procedure is to administer lithium or sodium valproate. To further optimize treatment, acetylcholinesterase inhibitors such as donepezil and galantamine have gained increased interest, though with conflicting (...) results. In the present randomized, double-blind, placebo-controlled clinical trial, we investigated whether, and to what extent, adjuvant rivastigmine might improve symptoms of mania in patients with BPD during the acute manic phase.A total of 70 patients with BPD in an acute state of mania (mean age 33.8 years; 24% females) took part in this study. After a thorough clinical interview, standard treatment consisted of 20mg/kg/day of sodium valproate; next, patients were randomly assigned either

2019 Neuropsychobiology Controlled trial quality: uncertain

10. Cognitive effects with rivastigmine augmentation of risperidone: A 12-month, randomized, double-blind, placebo-controlled study in schizophrenia. Full Text available with Trip Pro

Cognitive effects with rivastigmine augmentation of risperidone: A 12-month, randomized, double-blind, placebo-controlled study in schizophrenia. An important challenge in schizophrenia therapeutics is to develop an efficacious treatment for cognitive impairment. Acetylcholinesterase inhibitors, such as rivastigmine, have been studied for improving cognitive performance in these patients.Rivastigmine (uptitrated to 6 mg/day) was given as an add-on therapy to risperidone-treated stable (...) schizophrenia patients in a randomized, double-blind, placebo-controlled design. Of 67 patients who met eligibility criteria, 55 were recruited into the study. Twenty-eight were assigned to rivastigmine and 27 to placebo. These patients completed tests of attention, executive functioning, verbal skills, verbal and visuospatial working memory, and psychomotor speed on five occasions: at baseline, and at the end of the 1st, 3rd, 6th, and 12th months.The groups were similar in terms of sociodemographic profile

2019 Indian journal of psychiatry Controlled trial quality: uncertain

11. Cholinesterase inhibitor rivastigmine enhances nerve growth factor-induced neurite outgrowth in PC12 cells via sigma-1 and sigma-2 receptors. Full Text available with Trip Pro

Cholinesterase inhibitor rivastigmine enhances nerve growth factor-induced neurite outgrowth in PC12 cells via sigma-1 and sigma-2 receptors. Rivastigmine (Riv) is a potent and selective cholinesterase (acetylcholinesterase, AChE and butyrylcholinesterase, BuChE) inhibitor developed for the treatment of Alzheimer's disease (AD). To elucidate whether Riv causes neuronal differentiation, we examined its effect on nerve growth factor (NGF)-induced neurite outgrowth in PC12 cells. At concentrations

2018 PLoS ONE

12. Efficacy and safety of rivastigmine combined with memantine for Alzheimer' s Disease: a systematic review and meta-analysis

Efficacy and safety of rivastigmine combined with memantine for Alzheimer' s Disease: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2021 PROSPERO

13. Transdermal Rivastigmine Delivery for Alzheimer Disease: Amenability of Exposure Predictions of Rivastigmine and Metabolite, NAP226-90, by Linear Regression Model Using Limited Samples. (Abstract)

Transdermal Rivastigmine Delivery for Alzheimer Disease: Amenability of Exposure Predictions of Rivastigmine and Metabolite, NAP226-90, by Linear Regression Model Using Limited Samples. Although an optimized delivery of rivastigmine for management of Alzhiemer disease (AD) is provided by the transdermal patch, it is critical to establish a limited sampling strategy for the measurement of exposure of rivastigmine/NAP226-90.The relationship Cmax versus AUC0-24h for rivastigmine/NAP226-90 (...) was established by regression models. The derived regression equations enabled the prediction AUC0-24h for rivastigmine and NAP226-90. Models were evaluated using statistical criteria. Mixed model was used to predict AUC0-24h for rivastigmine/NAP226-90 from time points such as 8 (C8h), 12 (C12h), and 18 (C18h) hours.Excellent correlation was established for between Cmax and AUC0-24h for rivastigmine and NAP226-90. AUC0-24h predictions of either rivastigmine or NAP226-90 were within 0.8- to 1.25-fold

2017 Clinical neuropharmacology Controlled trial quality: uncertain

14. A Randomized Trial of Oral and Transdermal Rivastigmine for Postural Instability in Parkinson Disease Dementia. (Abstract)

A Randomized Trial of Oral and Transdermal Rivastigmine for Postural Instability in Parkinson Disease Dementia. The objective of this study was to compare the efficacy and safety of oral and transdermal rivastigmine for postural instability in patients with Parkinson disease dementia (PDD) who were candidates for a cholinesterase inhibitor. The primary outcome was the change in mean velocity of the center of pressure (CoP) after 6 months. Secondary outcomes included structural parameters (...) of dynamic posturography, clinical rating scales, and adverse events requiring dose reduction.Patients with PDD were randomized in a 1:1 ratio to oral or transdermal rivastigmine with target doses of 6 mg twice daily and 9.5 mg/10 cm daily, respectively. Outcomes were assessed at baseline and 6 months. Results were compared within and between groups.Nineteen patients completed the study (n = 8 oral, n = 11 transdermal). Mean daily doses of 9.4 (±1.5 mg) and 16.4 (±3.6 mg) were achieved in the oral

2018 Clinical neuropharmacology Controlled trial quality: uncertain

15. Bioequivalence Study of Rivastigmine 6 mg Capsules (Single Dose) in Healthy Volunteers. (Abstract)

Bioequivalence Study of Rivastigmine 6 mg Capsules (Single Dose) in Healthy Volunteers. To assess the bioequivalence of generic formulation of rivastigmine (test) and Exelon (reference).This randomized, open-label, 2-period, single-dose, 2-treatment, 2-sequence, crossover study was conducted in 40 healthy men under fed condition. Participants were randomized to receive a single dose of Exelon or rivastigmine capsule.A total of 31 participants completed the study. Area under the concentration (...) -time curve from time zero to time t (AUC0- t) and area under the concentration-time curve from time zero to infinity (AUC0-∞) for Exelon (mean [standard deviation], h·ng/mL) were 126.40 (56.95) and 129.46 (59.94), respectively, while they were 122.73 (43.46) and 125.08 (45.39) for rivastigmine. Geometric mean ratios of rivastigmine/Exelon were 99.17% for AUC0- t, 98.81% for AUC0-∞, and 105% for maximum observed plasma concentration ( Cmax). The 90% confidence intervals (CIs) were 94.14% to 104.46

2018 American journal of Alzheimer's disease and other dementias Controlled trial quality: uncertain

16. A Stability Indicating HPLC Assay Method for Analysis of Rivastigmine Hydrogen Tartrate in Dual-Ligand Nanoparticle Formulation Matrices and Cell Transport Medium Full Text available with Trip Pro

A Stability Indicating HPLC Assay Method for Analysis of Rivastigmine Hydrogen Tartrate in Dual-Ligand Nanoparticle Formulation Matrices and Cell Transport Medium The objective of this study was to develop and validate a method for quantitative analysis of rivastigmine hydrogen tartrate (RHT) in dual-ligand polymeric nanoparticle formulation matrices, drug release medium, and cellular transport medium. An isocratic HPLC analysis method using a reverse phase C18 column and a simple mobile phase

2018 Journal of analytical methods in chemistry

17. An update on the safety of current therapies for Alzheimer’s disease: focus on rivastigmine Full Text available with Trip Pro

An update on the safety of current therapies for Alzheimer’s disease: focus on rivastigmine Alzheimer's disease (AD) is the most common cause of major neurocognitive disorders worldwide. Despite all research efforts, therapeutic options for AD are still limited to two drug classes: cholinesterase inhibitors (ChEIs) and the NMDA-receptor antagonist memantine. Donepezil, rivastigmine and galantamine are the three ChEIs FDA-approved as first-line treatment for AD. Although they share the same (...) mode of action, they differ in terms of their pharmacologic characteristics and route of administration, which can impact their safety and tolerability profile. Rivastigmine, available in both oral and transdermal patch formulations, is a slowly reversible dual inhibitor of acetyl and butyryl cholinesterase, selective for the G1 isoform of acetylcholinesterase, without hepatic metabolism by the CYP-450 system. Despite its unique features, it has been associated with a higher incidence of adverse

2018 Therapeutic advances in drug safety

18. Direct Asymmetric Reductive Amination for the Synthesis of (S)-Rivastigmine Full Text available with Trip Pro

Direct Asymmetric Reductive Amination for the Synthesis of (S)-Rivastigmine In this article we demonstrate how asymmetric total synthesis of (S)-rivastigmine has been achieved using direct asymmetric reductive amination as the key transformation in four steps. The route started with readily available and cheap m-hydroxyacetophenone, through esterification, asymmetric reductive amination, N-diphenylmethyl deprotection and reductive amination, to provide the final (S)-rivastigmine in 82% overall

2018 Molecules : A Journal of Synthetic Chemistry and Natural Product Chemistry

19. Adverse drug events affecting medication persistence with rivastigmine patch application Full Text available with Trip Pro

Adverse drug events affecting medication persistence with rivastigmine patch application The rivastigmine transdermal patch, the only existing cholinesterase inhibitor available as a transdermal delivery system for treating Alzheimer's disease, has been reported to inhibit progression of cognitive impairment and impairment in activities of daily living, in addition to reducing care burden and improving adherence. However, application of the rivastigmine patch also frequently results in erythema (...) , pruritus, contact dermatitis, and other cutaneous adverse events at the application site, making it difficult to increase the effective dose and continue treatment. Therefore, we conducted a survey to examine the manifestation of adverse events and medication persistence in patients who were prescribed the rivastigmine patch.Three hundred and twelve patients diagnosed with Alzheimer's disease between July 1, 2011 and March 31, 2015 at the Toki Medical Clinic and who were prescribed a rivastigmine patch

2018 Patient preference and adherence

20. Rivastigmine Improves Appetite by Increasing the Plasma Acyl/Des-Acyl Ghrelin Ratio and Cortisol in Alzheimer Disease Full Text available with Trip Pro

Rivastigmine Improves Appetite by Increasing the Plasma Acyl/Des-Acyl Ghrelin Ratio and Cortisol in Alzheimer Disease Weight loss accelerates cognitive decline and increases mortality in patients with dementia. While acetylcholinesterase (AChE) inhibitors are known to cause appetite loss, we sometimes encounter patients in whom switching from donepezil (AChE inhibitor) to rivastigmine (AChE and butyrylcholinesterase [BuChE] inhibitor) improves appetite. Since BuChE inactivates ghrelin, a potent (...) orexigenic hormone, we speculated that rivastigmine improves appetite by inhibiting BuChE-mediated ghrelin inactivation.The subjects were patients with mild to moderate Alzheimer disease treated with either rivastigmine patch (n = 11) or donepezil (n = 11) for 6 months. Before and after treatment, we evaluated appetite (0, decreased; 1, slightly decreased; 2, normal; 3, slightly increased; 4, increased), cognitive function, and blood biochemical variables, including various hormones.Rivastigmine

2018 Dementia and geriatric cognitive disorders extra

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>